Having trouble viewing this email? Click here |
May 29, 2014
DynaMed Resident Focus is an outlet for residents to share recent evidence they find important with their peers. Residents who are members of the DynaMed community are eligible to participate. If interested, please email [email protected]. |
Clopidogrel Plus Aspirin Therapy for 3 Months Associated With Similar Mortality Rate Compared to 12 Month Therapy After Receiving Zotarolimus-eluting Stent Reference: JAMA 2013;310(23):2510-2522, (level 2 [mid-level] evidence) |
About the Author
Ben Davis, MD, is the co-chief resident of Swedish First Hill Family Medicine Residency Program. His current interests include clinical teaching, healthcare disparities, and Seattle sports. His blog, The Bad Humors, combines evidence-based medicine and humor to promote self-learning as well as peer teaching. |
As the use of drug-eluting stents in percutaneous coronary intervention (PCI) has become more common, physicians have grown more accustomed to seeing antiplatelet regimens on their patients� medication lists. Despite recommendations for limits on the duration of antiplatelet therapy, patients may continue to be on these potentially harmful medications long after they are indicated. Multiple, high-quality studies have looked at various antiplatelet regimens and durations but none so far have looked specifically at 3 versus 12 month courses of dual antiplatelet therapy in second generation stents, specifically zotarolimus-eluting. As drug-eluting stents become the standard over bare metal stents (due to their reduction in intra-stent thrombosis), physicians will have to be aware of what the optimal anti-platelet regimen is in order to balance the risks of intra-stent thrombosis with the harms of serious bleeding. |
DynaMed Contribution Opportunities
Dynamed Peer Review |
|
Quick Links
Share with Colleagues |
|
DynaMed EBM Focus DynaMed EBM Focus, Issue 21: DynaMed EBM Focus, Issue 22: |
|
DynaMed Events May 30- June 3, 2014
DynaMed Founder and Vice President Brian Alper, MD, will be attending the American Society of Clinical Oncology(ASCO) 50th Annual Meeting, held at McCormack Place in Chicago, Illinois. Representatives will be available to discuss peer review, mobile access, and free trial information. June 18, 2014 / 8am-12:30pm Senior Deputy Editor Alan Ehrlich, MD, will be attending the Massachusetts Medical Society (MMS) CME Event and Conference on Medical Marijuana: Regs, Responsibilities & Communication, held at the MMS Headquarters at Waltham Woods in Waltham, Massachusetts. Representatives will be available to discuss peer review, mobile access, and free trial information. |